WO2000020638A3 - Methods and compositions for the diagnosis and therapy of prostate cancer - Google Patents

Methods and compositions for the diagnosis and therapy of prostate cancer Download PDF

Info

Publication number
WO2000020638A3
WO2000020638A3 PCT/US1999/022575 US9922575W WO0020638A3 WO 2000020638 A3 WO2000020638 A3 WO 2000020638A3 US 9922575 W US9922575 W US 9922575W WO 0020638 A3 WO0020638 A3 WO 0020638A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosis
therapy
compositions
prostate cancer
Prior art date
Application number
PCT/US1999/022575
Other languages
French (fr)
Other versions
WO2000020638A9 (en
WO2000020638A2 (en
Inventor
Daniel E Afar
Rene S Hubert
Original Assignee
Urogenesys Inc
Daniel E Afar
Rene S Hubert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogenesys Inc, Daniel E Afar, Rene S Hubert filed Critical Urogenesys Inc
Priority to IL14231199A priority Critical patent/IL142311A0/en
Priority to CA002344563A priority patent/CA2344563A1/en
Priority to AU65024/99A priority patent/AU6502499A/en
Priority to EP99952982A priority patent/EP1117837A2/en
Publication of WO2000020638A2 publication Critical patent/WO2000020638A2/en
Publication of WO2000020638A9 publication Critical patent/WO2000020638A9/en
Publication of WO2000020638A3 publication Critical patent/WO2000020638A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)

Abstract

Methods and compositions for the diagnosis and therapy of prostate cancer are described. The methods of the invention utilize isolated polynucleotides corresponding to the human Y-specific gene TSPY (testis-specific protein Y-encoded) (Arnemann, J et al., 1991, Genomics 11: 108-114), proteins encoded by the TSPY gene and fragments thereof, and antibodies capable of specifically recognizing and binding to TSPY proteins.
PCT/US1999/022575 1998-10-02 1999-10-02 Methods and compositions for the diagnosis and therapy of prostate cancer WO2000020638A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL14231199A IL142311A0 (en) 1998-10-02 1999-10-02 Methods and compositions for the diagnosis and therapy of prostate cancer
CA002344563A CA2344563A1 (en) 1998-10-02 1999-10-02 Methods and compositions for the diagnosis and therapy of prostate cancer
AU65024/99A AU6502499A (en) 1998-10-02 1999-10-02 Methods and compositions for the diagnosis and therapy of prostate cancer
EP99952982A EP1117837A2 (en) 1998-10-02 1999-10-02 Methods and compositions for the diagnosis and therapy of prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10289398P 1998-10-02 1998-10-02
US60/102,893 1998-10-02

Publications (3)

Publication Number Publication Date
WO2000020638A2 WO2000020638A2 (en) 2000-04-13
WO2000020638A9 WO2000020638A9 (en) 2000-10-05
WO2000020638A3 true WO2000020638A3 (en) 2000-11-09

Family

ID=22292250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022575 WO2000020638A2 (en) 1998-10-02 1999-10-02 Methods and compositions for the diagnosis and therapy of prostate cancer

Country Status (5)

Country Link
EP (1) EP1117837A2 (en)
AU (1) AU6502499A (en)
CA (1) CA2344563A1 (en)
IL (1) IL142311A0 (en)
WO (1) WO2000020638A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085121A2 (en) * 2002-04-01 2003-10-16 Agensys, Inc. Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012709A2 (en) * 1998-08-31 2000-03-09 Urogenesys, Inc. Phelix: a testis-specific protein expressed in cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012709A2 (en) * 1998-08-31 2000-03-09 Urogenesys, Inc. Phelix: a testis-specific protein expressed in cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARNEMANN J ET AL.: "Cloning and sequence analysis of a human Y-chromosome-derived, testicular cDNA, TSPY", GENOMICS, vol. 11, 1991, pages 108 - 114, XP000925606 *
FAI, Y AND LAU, C: "Gonadoblastoma, testicular and prostate cancer, and the TSPY gene", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 64, 1999, pages 921 - 927, XP000925603 *
REITER ET AL: "PROSTATE STEM CELL ANTIGEN: A CELL SURFACE MARKER OVEREXPRESSED IN PROSTATE CANCER", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, no. 95, 1 February 1998 (1998-02-01), pages 1735 - 1740, XP002078363, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2000020638A9 (en) 2000-10-05
AU6502499A (en) 2000-04-26
IL142311A0 (en) 2002-03-10
WO2000020638A2 (en) 2000-04-13
CA2344563A1 (en) 2000-04-13
EP1117837A2 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
UA102988C2 (en) ISOLATED HUMAN ANTIBODY, OR AN ANTIGEN-BINDING PORTION THEREOF THAT SPECIFICALLY BINDS TO HUMAN TNFα, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD FOR TREATING A DISORDER IN WHICH TNFα ACTIVITY IS DETRIMENTAL
TW428026B (en) Bifunctional protein, preparation and use
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001055308A3 (en) Nucleic acids, proteins, and antibodies
WO1999020756A3 (en) Human toll homologues
AU3461797A (en) Fas ligand-like protein, its production and use
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
AU2633497A (en) Peptides having antiproliferative properties
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO1996031603A3 (en) Methods and compositions for regulating fadd
WO1998011234A3 (en) Human protein kinases
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO2001008635A3 (en) Calcium channel transport polynucleotides, polypeptides, and antibodies
EP0921194A3 (en) TRAILLK-2: a member of the TNF ligand family
WO1998018822A3 (en) Novel human lim proteins
WO1998025956A3 (en) Human GTP-binding proteins
EP0815240A4 (en) Novel human cyclin-dependent kinase-like proteins and methods of using the same
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
WO2000020638A3 (en) Methods and compositions for the diagnosis and therapy of prostate cancer
EP0919620A3 (en) TRAILLK-3: a member of the TNF ligand family
WO2003048317A3 (en) Antibodies to magmas and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 65024

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AT AT AU BR CA CH CN DE DE DK DK ES FI FI GB IL JP KR MX NO NZ RU SE SG US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AT AT AU BR CA CH CN DE DE DK DK ES FI FI GB IL JP KR MX NO NZ RU SE SG US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AT AU BR CA CH CN DE DE DK DK ES FI FI GB IL JP KR MX NO NZ RU SE SG US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2344563

Country of ref document: CA

Ref country code: CA

Ref document number: 2344563

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 65024/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999952982

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09806352

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999952982

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999952982

Country of ref document: EP